Currentblue cross blue shield - tennesseePolicy N/A

General Inflammation Testing (CRP and ESR) — Coverage and Reimbursement Guidance

Coverage and reimbursement guidance for laboratory measurement of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) for evaluation and monitoring of inflammatory conditions; applies to Blue Cross Blue Shield - Tennessee members and providers submitting claims.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyGeneral Inflammation Testing (CRP and ESR) — Coverage and Reimbursement Guidance

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes in this revision.

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionOrder CRP or ESR testing only when tied to a diagnosed or suspected inflammatory condition and document the condition to support testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2primary tests covered

multiplelisted indications

1-3 moRA initial frequency

3-6 mo→lessHodgkin ESR cadence

13.1CRP DOR for PJI

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Covered Indications and Uses

Monitoring and evaluation of inflammatory diseases

Reimbursement table guidance: test preference and monitoring frequency for covered indications

Monitoring and evaluation of inflammatory diseases: Follow the reimbursement table for test preference (CRP, ESR, or both) and recommended monitoring frequency by condition (examples: RA: 1-3 months initially then 6-12 months; Hodgkin lymphoma: every 3-6 months for 1-2 years then every 6-12 months for 3 years then annually; PMR: at diagnosis and every 3 months during long-term steroid therapy).

Providers should follow listed test preference per indication.

Evaluation and supportive diagnosis of periprosthetic joint infection (PJI)

PJI supportive evaluation: Use CRP and ESR as supportive minor criteria in PJI workup; CRP shows higher diagnostic odds ratio than ESR in meta-analysis, but both may be falsely normal with low-virulence organisms; interpret results in the clinical context and consider microbiologic testing and imaging.

Berbari et al. meta-analysis and Parvizi/MSIS guidance.

Staging and follow-up of Classic Hodgkin Lymphoma

Hodgkin lymphoma staging/follow-up: ESR is essential in initial staging/workup and follow-up per NCCN; an ESR >=50 mm/h is considered an early-stage unfavorable factor that influences treatment algorithms and radiation dosing. Follow-up frequency for ESR when elevated at diagnosis: every 3-6 months for 1-2 years, then every 6-12 months for 3 years, then annually.ESR >=50 mm/h

Per NCCN and ACR follow-up guidance.

Workup and monitoring of polymyalgia rheumatica and Castleman disease

PMR and Castleman disease: For PMR, perform baseline ESR and/or CRP prior to initiating long-term steroid therapy and monitor markers every three months during therapy. For idiopathic Multicentric Castleman Disease (MCD), CRP elevation (>10 mg/L) is a mandatory minor diagnostic criterion and tracking CRP is highly recommended; ESR is accepted if CRP is not available.CRP >10 mg/L or ESR >15 mm/h

Per BSR/BHPR for PMR and NCCN for Castleman disease.

Rheumatoid arthritis disease activity assessment

RA disease activity assessment: Either CRP or ESR may be used in DAS28 and other validated RA disease activity measures; acute-phase reactants are required in some composite scores and monitoring frequency should be monthly to every 1-3 months when disease is active and less frequent when stable.

Per ACR, EULAR, NCC-CC and large cohort studies (Hamann et al., Watson et al.).

Diagnosis and monitoring of GCA, PMR, RA, SLE, PJI, pediatric AHO, MIS-C, and other inflammatory conditions where CRP/ESR are part of validated measures or algorithms

Diagnosis and monitoring of inflammatory conditions where CRP/ESR are part of validated measures or algorithms

GCA/PMR/RA/SLE/PJI/MIS-C/other conditions: CRP and/or ESR are part of validated diagnostic algorithms and disease activity measures across multiple conditions (GCA, PMR, RA, SLE, PJI, pediatric AHO, MIS-C). CRP is often preferred for sensitivity and rapid change; ESR may be used in combination with CRP in select conditions for higher sensitivity.

Guideline recommendations summarized from BSR/BHPR, ACR, EULAR, MSIS, PIDS/IDSA.

Inflammatory and rheumatologic conditions recommended by specialty guidelines

Guideline-recommended indications: Specialty society guidelines (EULAR, ACR, BSR/BHPR, NCC-CC, MSIS, AAOS, PIDS/IDSA) recommend use of CRP and/or ESR at baseline and for monitoring in a range of inflammatory and rheumatologic conditions including RA, PMR, GCA, ankylosing spondylitis and PJI; frequency and test preference vary by guideline and condition.

See reimbursement table and referenced guidelines for details.

Rheumatologic diseases and evaluation of suspected infection or PJI — cited via guideline and research references

Referenced evidence base: The policy references multiple guideline and research sources (BSR/BHPR, EULAR, ACR, NCCN, MSIS, AAOS, PIDS/IDSA, large cohort and meta-analyses) to support indications, test preferences, and monitoring frequencies summarized in the reimbursement table.

Bibliography lists the detailed citations.

Coding and Numeric Thresholds

Applicable CPT/HCPCS Procedure CodesCPT

85651	Sedimentation rate, erythrocyte; non-automated.
85652	Sedimentation rate, erythrocyte; automated.
86140	C-reactive protein

Applicable CPT/HCPCS procedure codesmixed

No codes listed

No billing codes listed in this sectionmixed

No codes listed

inv-21: ESR threshold — Hodgkin lymphoma

ThresholdESR ≥ 50 mm/h is considered an early-stage unfavorable factor in Classic Hodgkin lymphoma and influences staging/treatment algorithms (e.g., selection of HODG-6 and potential ISRT).

ContextNCCN lists ESR as 'essential' in HL workup and recommends testing within 6 months of diagnosis; elevated ESR at diagnosis informs follow-up cadence.

Follow-up implicationAn initial ESR ≥50 may alter radiation dosing and treatment pathway (example: non-bulky stage I-IIA with ESR <50 may receive lower ISRT dose).

inv-22: PJI sensitivity cutoffs

PJI high-sensitivity cutoffsESR cutoff 10 mm/h and CRP cutoff 5 mg/L achieved ≥95% sensitivity in a PJI cohort (Bingham et al., 2019).

Recommended Testing Frequency

inv-64: CRP and/or ESR as specified

Variable monitoring cadenceMonitoring frequency for CRP and/or ESR varies by condition — e.g., RA: 1–3 months initially then 6–12 months; Hodgkin lymphoma: every 3–6 months for 1–2 years then 6–12 months then annually.

Condition-specific examplesPMR/GCA: test at diagnosis and during follow-up visits; PMR monitoring every 3 months during long-term steroid therapy.

Composite measure useCRP or ESR may be used within validated composite disease activity measures (DAS28, SDAI, CDAI, RAPID3) with frequency tied to disease activity.

inv-65: ESR (when elevated at initial Hodgkin lymphoma diagnosis) and other routine labs

Follow-up schedule when ESR initially elevatedIf ESR is elevated at initial Hodgkin lymphoma diagnosis, perform routine labs including ESR every 3–6 months for 1–2 years, then every 6–12 months for the next 3 years, then annually.

Provider Actions and Documentation

Documentation Required

Condition documentation and general exam guidance

Measure ESR and/or CRP only when clinically indicated. Coverage is designated based on a diagnosed or suspected inflammatory condition; documentation must state the diagnosis or suspected condition. Measurement of CRP and/or ESR during a routine general exam without abnormal findings does not meet coverage criteria and may be denied. If there is any conflict with applicable government policy (LCD/NCD or state Medicaid), the government policy takes precedence.

Condition documentation required: Document the diagnosed or suspected inflammatory condition when ordering ESR and/or CRP.
Routine general exam: CRP/ESR during a general exam without abnormal findings does not meet coverage criteria.

Documentation Required

Rheumatoid arthritis — active disease monitoring

For rheumatoid arthritis (RA) with active disease, monitor disease activity and inflammatory markers regularly. Guidelines recommend measuring CRP and key components of disease activity (using a composite score such as DAS28) monthly in people with recent-onset active RA until disease is controlled, and using CRP (or ESR within DAS28) every 1–3 months during active disease as part of treatment decision-making.

Ordering Requirements

Documentation Required

Order tests only with documented inflammatory diagnosis/suspicion

Orders for ESR or CRP should be tied to a diagnosed or suspected inflammatory condition and documented in the medical record to support medical necessity.

Policy: Measurement of ESR and/or CRP meets coverage criteria for inflammatory conditions as specified in Note 1.
Ordering should be tied to the diagnosed or suspected condition and documented accordingly.

Note

Align orders with specialty guideline recommendations

When guideline‑directed, testing is typically ordered by the treating specialist (e.g., oncology for Hodgkin lymphoma, rheumatology for PMR/RA); orders should align with specialty guidance where applicable.

EULAR/ACR and specialty guidance referenced for condition‑specific monitoring.

Documentation Required

Not Covered / Low-Value Uses

Measurement of CRP and/or ESR during a routine general examination without abnormal findings is explicitly listed as not covered and may be denied. Orders must be supported by documentation of a diagnosed or suspected inflammatory condition to meet coverage criteria.

Evidence and reviews indicate that using ESR alone as a screening predictor for rheumatoid arthritis or systemic lupus erythematosus has limited predictive value and low positive predictive value in primary care populations. CRP may offer superior performance for acute-phase detection, and routine ESR-only screening is therefore of limited utility.

Routine use of ESR as a standalone surveillance test for Hodgkin lymphoma relapse has limited supporting evidence and low utility; many recurrences are detected by history and physical examination rather than routine blood testing, so standalone ESR surveillance without clinical indication is not favored.

Professional guidance from the ASCP Choosing Wisely campaign specifically recommends against ordering an ESR to look for inflammation in patients with undiagnosed conditions and instead recommends ordering CRP to detect acute-phase inflammation. This reflects ESR’s lower sensitivity early in disease and its slower return to baseline compared with CRP.

The referenced sections cited here (bibliography and related materials) do not list additional explicit tests or indications as not covered beyond those already stated in the policy excerpts.

Background and Rationale

CRP and ESR are non-specific acute-phase reactants used to detect and monitor inflammation from diverse causes. The policy specifies that measurement meets coverage criteria when ordered for identified inflammatory conditions, and conversely that testing during an otherwise normal general exam does not meet coverage criteria.

Definitions

inv-48: CRP definition

CRPC-reactive protein (CRP).

Definition contextCRP is an acute-phase reactant measured in serum/plasma; FDA has review criteria for conventional and high-sensitivity CRP assays.

Regulatory noteMultiple FDA-approved CRP assays exist; LDTs for CRP must be validated and performed in CLIA-regulated labs.

inv-49: ESR definition

ESRErythrocyte sedimentation rate (ESR) — commonly measured by the Westergren method.

Analytic considerationsESR is influenced by sample preparation, anticoagulant (citrate vs EDTA), red cell morphology and ambient conditions; ICSH provides method recommendations.

References and Guideline Citations

Policy Summary

Payerblue cross blue shield - tennessee

PolicyGeneral Inflammation Testing (CRP and ESR) — Coverage and Reimbursement Guidance

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes in this revision.

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionOrder CRP or ESR testing only when tied to a diagnosed or suspected inflammatory condition and document the condition to support testing.

SourceLink

On This Page

Standard cutoffs noteAuthors note standard MSIS cutoffs (ESR 30 mm/h, CRP 10 mg/L) may yield lower sensitivity and more false positives compared with lower thresholds.

Combined performanceCombined ESR 10 mm/h and CRP 5 mg/L produced 100% sensitivity in the cited study cohort.

inv-23: Castleman disease minor diagnostic thresholds

Castleman minor diagnostic thresholdsMinor diagnostic criteria for idiopathic Multicentric Castleman Disease include CRP >10 mg/L OR ESR >15 mm/h (NCCN).

CRP priorityNCCN states elevation of CRP is mandatory and tracking CRP is highly recommended; ESR accepted only if CRP not available.

Use in workupCRP and ESR are listed among essential laboratory tests (LDH, CRP, ESR) for B‑cell lymphoma/Castleman workup.

inv-24: Hodgkin lymphoma unfavorable ESR threshold

Unfavorable ESR cutoffESR ≥ 50 mm/h is identified as an unfavorable prognostic factor in early-stage Classic Hodgkin lymphoma.

Clinical effectAn ESR ≥50 can change the recommended treatment algorithm and influence decisions about involved-site radiation therapy dosing.

Guideline sourceDesignation based on NCCN Hodgkin Lymphoma guidance as an 'early-stage unfavorable factor'.

inv-25: Pediatric MIS-C lab thresholds (tiering example)

MIS-C tiering thresholdsACR MIS-C algorithm: proceed to tier 2 cardiac testing if tier 1 labs show CRP ≥5 mg/L OR ESR ≥40 mm/hr plus another suggestive lab feature (e.g., neutrophilia or platelet <150,000/µL).

Tier 1 labsTier 1 routine labs include CBC, CMP, ESR and CRP as initial screening for suspected MIS-C.

Example suggestive featuresA single threshold (CRP ≥5 or ESR ≥40) requires an additional suggestive laboratory feature to trigger tier 2 testing.

inv-26: No numeric test thresholds specified

Policy statementNo specific numeric test thresholds are provided for many covered indications; frequency and test preference vary by condition and guideline.

ExamplesReimbursement table often lists test preference (CRP, ESR or both) and frequency but not numeric cutoffs for most conditions (e.g., arthritis, PMR, GCA).

Laboratory guidanceFDA and guideline references discuss assay types (CRP, hsCRP) and ESR methods but do not define universal numeric thresholds for routine monitoring.

NCCN lists ESR as 'essential' in HL workup and includes it in scheduled follow-up labs.

Role in stagingESR result at diagnosis (e.g., <50 vs ≥50) is used to guide staging-based treatment pathways.

inv-66: ESR and CRP as part of composite measures in early arthritis

Early arthritis monitoring intervalAssess disease activity at 1–3 month intervals until treatment target reached, then every 6–12 months (EULAR recommendations).

Composite measuresESR and CRP are used as components of composite measures (e.g., DAS28, SDAI) to assess disease activity in early arthritis.

Treatment adjustmentFrequent monitoring (1–3 months) is recommended to guide treat-to-target strategies in early arthritis.

inv-67: CRP/ESR monitoring cadence

Active disease monitoring frequencyWhen disease is active, monitor CRP/ESR monthly or every 1–3 months until control; once stable, monitor every 6–12 months.

RA guidanceNCC-CC and ACR recommend monthly measures (including CRP) until disease is controlled; ACR recommends at least annual assessment and more frequently if active.

Composite use and logisticsCRP/ESR inclusion in composite scores may affect timing and logistics of point-of-care decision-making.

inv-68: ESR or CRP — PMR monitoring

PMR steroid-therapy monitoringMonitor ESR or CRP every three months during long-term steroid therapy for polymyalgia rheumatica.

Initial testingObtain ESR and/or CRP prior to initiating long-term steroid therapy for PMR.

Visit-based monitoringBSR/BHPR recommend inflammatory markers (ESR/CRP) at each follow-up visit for GCA/PMR management.

inv-69: ESR — Hodgkin lymphoma follow-up frequency

Infrequent Hodgkin follow-up variantsSome Hodgkin lymphoma follow-up variants recommend ESR testing 1–2 times per year.

Limited utility noteACR notes limited data supporting routine bloodwork for relapse detection; many recurrences detected by history/physical rather than routine labs.

Variant-dependent appropriatenessAppropriateness ratings in ACR variants range from 'usually not appropriate' to 'usually appropriate' for ESR use.

inv-70: CRP and ESR — guideline examples

Guideline variabilityGuideline-recommended CRP/ESR monitoring varies: examples include monthly until disease control for RA, 1–3 months during active arthritis, and monthly/visit-based monitoring for PMR/GCA.

Use in composite scoresCRP and ESR are often embedded within validated composite disease activity measures, affecting monitoring schedules.

Individualize by conditionFrequency should be tailored to condition, disease activity, and specialty guidance.

inv-71: No frequency limits specified

No universal frequency limitsThe policy does not specify universal frequency limits for CRP/ESR testing across indications; frequency is governed by condition-specific guidance.

Reimbursement table guidanceProviders should follow the reimbursement table and specialty guidelines for test frequency and preference per condition.

Regulatory referencesFDA and CLIA references address assay methods and validation but do not define testing frequency limits.

RA active disease monitoring guidance: measure CRP and disease activity (eg, DAS28, CDAI, SDAI) monthly in recent-onset active RA; during active disease assess CRP (or ESR in validated composite scores) every 1–3 months.

Documentation Required

Giant cell arteritis — baseline labs and documentation

When initiating high‑dose glucocorticoids for suspected giant cell arteritis (GCA), document clinically relevant symptoms and obtain baseline laboratory markers. Obtain full blood count, CRP, and ESR before or immediately after starting treatment; treatment should not be delayed if clinical suspicion is high.

Documentation at GCA treatment initiation: document symptoms/signs and obtain baseline CBC, CRP, and ESR before or immediately after starting glucocorticoids.
Do not delay first dose of glucocorticoid if GCA is strongly suspected.

Documentation Required

Oncology — Hodgkin lymphoma and Castleman disease documentation

Follow oncology guideline–driven documentation when ordering ESR or CRP. For Hodgkin lymphoma, document ESR use per NCCN staging/workup and follow-up schedules; for Castleman disease document CRP and/or ESR as part of workup and note that elevated CRP (>10 mg/L) is a minor diagnostic criterion for idiopathic multicentric Castleman disease.

Oncology-related documentation: Hodgkin lymphoma — ESR is listed as 'essential' within 6 months of diagnosis and during follow-up (every 3–6 months for 1–2 years, then every 6–12 months for 3 years, then annually).
Castleman disease — NCCN lists LDH, CRP, and ESR as essential; elevation of CRP (>10 mg/L) is a minor diagnostic criterion and tracking CRP is recommended (ESR acceptable if CRP unavailable).

Note

ESR versus CRP ordering guidance

Prefer CRP over ESR to detect acute phase inflammation when appropriate. CRP rises earlier (within 24 hours) and returns to normal faster after resolution of inflammation or removal of the inciting cause; ESR can remain elevated for days due to fibrinogen. Professional guidance discourages ordering ESR alone to look for acute inflammation in undifferentiated conditions.

ESR vs CRP ordering guidance: order CRP to detect acute phase inflammation; ESR may be less sensitive in the first 24 hours and lags in normalization.

Denial Risk

Hodgkin lymphoma — limited utility of routine ESR

Routine blood tests including ESR have limited utility for detecting Hodgkin lymphoma relapse; most recurrences are detected by history and physical exam rather than routine labs. Use ESR in Hodgkin lymphoma per guideline-specified schedules rather than routine, low‑yield testing.

Low-yield routine ESR in Hodgkin lymphoma: acknowledge ACR guidance that routine blood work has limited role in relapse detection; follow NCCN-specified schedules when indicated.

Billing Rule

Procedure codes and prior authorization note

Applicable CPT/HCPCS procedure codes for ordering and billing: 85651 (ESR, non-automated), 85652 (ESR, automated), and 86140 (C-reactive protein). Verify any prior authorization requirements in the payer system; this policy does not specify additional prior authorization triggers.

Procedure codes for ordering/authorization: CPT 85651, 85652, 86140.
Prior authorization: No explicit authorization or denial triggers specified in this section; verify member-specific prior authorization requirements in payer systems and government policies.

Step Therapy

Step therapy

Step therapy: None specified for ESR or CRP in this policy. There are no step‑therapy requirements described for ordering these tests.

No step therapy requirements described for ESR/CRP testing.

Note

Literature and guideline support

This section provides literature and guideline citations supporting clinical use of CRP and ESR (eg, BSR/BHPR, EULAR, ACR, NCCN, ASCP, FDA guidance, Pediatric ID/IDSA) which inform appropriate ordering, monitoring intervals, and interpretation across conditions.

Literature and guideline sources: BSR/BHPR for GCA and PMR; NCCN for lymphomas and Castleman disease; ASCP Choosing Wisely; ACR guidance; Pediatric Infectious Diseases Society/IDSA for AHO; FDA device and CRP assessment guidance.

Order CRP/ESR with documented clinical assessment (eg, before GCA steroids)

Testing should be ordered in the context of a documented clinical assessment—for example, obtain CRP/ESR prior to or immediately after initiating high‑dose glucocorticoids for suspected GCA.

BSR: obtain full blood count and CRP/ESR before or immediately after commencing high‑dose glucocorticoids for suspected GCA.

Billing Rule

Comply with government policies and use CLIA‑certified labs

Orders must comply with applicable government policies and testing should be performed in CLIA‑certified laboratories; laboratory‑developed tests require in‑house validation per CMS/CLIA rules.

Policy disclaimer: government policies (LCD/NCD/state Medicaid) take precedence.
Testing performed in CLIA‑certified labs; LDTs are regulated by CMS and must be validated.

Note

No ordering‑provider restrictions stated

The policy text does not impose specific restrictions on which provider types may order ESR or CRP; no specialist‑only ordering requirement is specified.

ESR is a nonspecific marker of inflammation used in staging and management algorithms for conditions such as Hodgkin lymphoma.

inv-50: CRP — rapid response

CRP dynamicsCRP rises rapidly in response to inflammation and infection and returns toward baseline quickly after resolution.

Clinical sensitivityCRP is more sensitive than ESR for acute infection and increases within the first 24 hours of a disease process.

LimitationsCRP may be suppressed in some conditions (e.g., SLE) and does not always mirror disease progression in all disorders.

inv-51: ESR — characteristics

ESR characteristicsESR is a nonspecific inflammatory marker influenced by fibrinogen and immunoglobulin levels; it may remain elevated longer than CRP after source removal.

Use in stagingESR is used in staging algorithms (e.g., Hodgkin lymphoma) and can denote unfavorable prognosis when markedly elevated.

Preanalytic effectsESR results can be significantly affected by sample preparation and assay method, impacting comparability across labs.

inv-52: DAS28 / SDAI / CDAI / RAPID3

Composite measuresDAS28, SDAI, CDAI, RAPID3 are validated RA disease activity measures that may incorporate CRP or ESR values.

DAS28 variantsDAS28 can be calculated with either CRP or ESR; DAS28-CRP scores are ~0.3 lower than DAS28-ESR on average and may need adjustment.

Clinical useInclusion of an acute-phase reactant is required for some composite scores used to guide RA management.

inv-53: LDT — regulatory note

LDTsLaboratory-developed tests (LDTs) are developed/performed in-house and must be validated; they are regulated by CMS under CLIA as high-complexity tests.

Regulatory statusLDTs are not FDA-approved but are subject to CLIA quality standards and laboratory validation requirements.

Laboratory responsibilityMany laboratories use LDTs for CRP/ESR assays and must ensure appropriate validation and quality control.

inv-54: CRP/hsCRP/cCRP — FDA review

FDA CRP guidanceFDA has published review criteria for CRP assays including hsCRP and cardiac CRP variants (FDA guidance referenced).

Assay typesFDA-approved assay types include conventional CRP, high-sensitivity CRP (hsCRP), and cardiac CRP (cCRP).

Device listingsFDA device databases list multiple approved CRP and ESR systems; consult device listings for specific assay approvals.

inv-55: ESR — ICSH recommendations

ESR method referencesICSH recommendations describe modified and alternate methods for measuring the erythrocyte sedimentation rate; method differences can affect results.

Method variabilityComparisons between Westergren and automated/EDTA-based methods show significant variability (R2 ~0.72 in one study).

Standardization importanceBe aware of assay method used (Westergren vs automated) when interpreting ESR values across labs.